4Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)[ corrected ].J Clin Oncol,2003,21 (12):2237-2246.
5Tamura K,Fukuoka M.Gefitinib in non-small cell lung cancer.Expert Opin Pharmacother,2005,6(6):985-993.
6Konishi J,Yamazaki K,Kinoshita I,et al.Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.Anticancer Res,2005,25(1B):435-441.
7Lange T,Muller Tidow C,Serve H,et al.First-line systemic treatment with gefitinib in stage Ⅳ non-small cell lung cancer.Oncol Rep,2005,14 (6):1539-1542.
8Su WP,Yang CH,Yu C J,et al.Gefitinib treatment for non-small cell lung cancer a study including patients with poor performance status.J Formos Med Assoc,2005,104(8):557-562.
9Ge G,Wu J,Wang Y,et al.Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase.Biochem Biophys Res Commun,2002,290 (3):914-920.
10Ciardiello F,Caputo R,Borriello G,et al.ZD1839 (IRESSA),an EGFR-selective tyrosine kinase inhibitor,enhances taxane activity in bcl-2 overexpressing,multidrug-resistant MCF-7 ADR human breast cancer cells.Int J Cancer,2002,98 (3):463-469.
